| December 2006 |
Protherics’ raises £38 million to:
- acquire MacroMed Inc, a privately owned speciality drug development and manufacturing company based in the US for lead product OncoGel™ for the treatment of oesophageal and brain cancers
- in-license IP from Glenveigh Pharmaceuticals LLC for the use of DigiFab™ and GSK’s Digibind® in the treatment of pre-eclampsia and eclampsia
- in-license IP from Advanced In Vitro Cell Technologies for the use and
co-development of acadesine in the treatment of B-cell chronic
lymphocytic leukaemia (B-CLL) |
|
|
| December 2005 |
Major licensing deal with AstraZeneca for the development and commercialisation of Protherics' anti-sepsis product CytoFab™ Protherics could receive $340m in upfront and milestone payments, in addition to a 20% royalty on net global sales |
| |
| July 2005 |
Voraxaze™ Marketing Authorisation Application (MAA) submitted to EU regulatory agencies |
|
|
| September 2004 |
Transfer of the Porton Down research facility and out-licensing of early stage research acquired with Enact Pharma to two UK start-up companies |
| |
| July 2004 |
£9.3m (net of expenses) Placing and Open Offer announced to fund a US and European sales and marketing function and manufacturing improvements |
| |
| June 2004 |
Maiden profits announced for the financial year which ended on the 31st March 2004 |
| |
| June 2003 |
Acquisition of Enact Pharma PLC and completion of a £3m fundraising |
| |
| February 2002 |
US launch of DigiFab™, a treatment for the toxic effects of overdosage with the heart drug digoxin |
| |
| Spring 2001 |
US launch of CroFab™, the first new rattlesnake antivenom on the US market in 50 years |
| |
| September 1999 |
Protherics PLC was formed from the merger of Proteus International Plc and Therapeutic Antibodies Inc. |